MindWalk (NASDAQ:HYFT) Upgraded at Zacks Research

MindWalk (NASDAQ:HYFT) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

Several other equities research analysts have also recently commented on HYFT. Wall Street Zen raised shares of MindWalk from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. HC Wainwright reissued a “buy” rating on shares of MindWalk in a report on Monday, July 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.00.

MindWalk Price Performance

HYFT opened at $1.48 on Monday. The company has a quick ratio of 1.75, a current ratio of 1.84 and a debt-to-equity ratio of 0.43. MindWalk has a 12 month low of $0.99 and a 12 month high of $2.99. The company has a fifty day simple moving average of $1.36 and a 200 day simple moving average of $1.37. The stock has a market cap of $69.13 million, a P/E ratio of -5.69 and a beta of 0.82.

MindWalk (NASDAQ:HYFT) last posted its earnings results on Monday, September 14th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The business had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.25 million. MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%. On average, research analysts expect that MindWalk will post -0.21 EPS for the current year.

Hedge Funds Weigh In On MindWalk

An institutional investor recently bought a new stake in MindWalk stock. BlackRock Inc. purchased a new position in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned about 0.33% of MindWalk at the end of the most recent quarter. 6.70% of the stock is currently owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.